SRR1466975
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.649
- INTERFERON_ALPHA_RESPONSE+0.575
- INFLAMMATORY_RESPONSE+0.545
- IL6_JAK_STAT3_SIGNALING+0.534
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.519
- INTERFERON_GAMMA_RESPONSE+0.509
- UNFOLDED_PROTEIN_RESPONSE+0.508
- CHOLESTEROL_HOMEOSTASIS+0.496
- APOPTOSIS+0.477
- MYC_TARGETS_V2+0.474
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.330
- KRAS_SIGNALING_DN-0.286
- E2F_TARGETS-0.211
- HEDGEHOG_SIGNALING-0.198
- SPERMATOGENESIS-0.136
- G2M_CHECKPOINT-0.135
- MITOTIC_SPINDLE-0.098
- UV_RESPONSE_DN-0.058
- APICAL_SURFACE-0.015
- PROTEIN_SECRETION+0.016
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1410783 | GTEX | — | 0.967 |
| 2 | SRR1480652 | GTEX | — | 0.940 |
| 3 | SRR820209 | GTEX | — | 0.933 |
| 4 | SRR1331579 | GTEX | — | 0.926 |
| 5 | SRR820133 | GTEX | — | 0.921 |
| 6 | A3874F0D-53A9-43C8-87EE-65C12C0F8135 | — | — | 0.910 |
| 7 | MDT-AP-2001 | Med | Medulloblastoma | 0.910 |
| 8 | CCA161B9-1E9A-4F8C-8144-B32B5CF76ECC | — | — | 0.906 |
| 9 | SRR821019 | GTEX | — | 0.897 |
| 10 | F9A39954-57EB-4A3F-97A0-1801B08BBD53 | — | — | 0.894 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.649 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.575 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.545 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.534 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.519 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.509 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.508 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.496 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.477 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.474 | Idelalisib | — uncovered |
| HYPOXIA | 0.430 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.424 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.420 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.411 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.405 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.404 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.398 | Idelalisib | — uncovered |
| COAGULATION | 0.398 | Binimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.390 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.380 | Inavolisib | — uncovered |